Who We Are

Reneo is a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases including mitochondrial diseases with significant unmet medical needs.

Our Work

Reneo is initially developing REN001 in two rare genetic diseases that typically present with myopathy: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).

 

We completed a Phase 1b clinical trial in patients with PMM and are currently enrolling patients in a global Phase 2b clinical trial (STRIDE Study). In addition, we conducted two exploratory Phase 1b clinical trials of REN001 in patients with LC-FAOD and McArdle disease, respectively.

Leadership Team

Meet the Reneo Executive Team!

Reneo-Greg-050222

Gregory J. Flesher

President & Chief Executive Officer

leader-3

Alejandro Dorenbaum, M.D.

Chief Medical Officer

1L4A1519_EDIT-IMG

Ashley F. Hall, J.D.

Chief Development Officer

Reneo-IMG_050222

Michael P. Cruse

Chief Operating Officer

leader-2

Wendy S. Johnson, MBA

Chief Business Officer

purkinslynn

Lynn Purkins, Ph.D.

Senior Vice President of Clinical Operations

Board of Directors

Partner
With Reneo

Reneo works with investor partners to enable continued progress in our clinical development programs.

MIKE GREY

Executive Chairman

Roshawn Blunt

Executive Chairman

Eric Dube, Ph.D.

GREGORY J. FLESHER

President & Chief Executive Officer

Paul W. Hoelscher

Ed Mathers

Bali Muralidhar

Niall O’Donnell

Stacey D. Seltzer